Updated Survival Results From DESTINY-Breast01 of T-DXd in Metastatic Breast Cancer
Posted: Thursday, October 21, 2021
Previous reports of the phase II DESTINY-Breast01 trial, conducted by Cristina Saura Manich, MD, PhD, of Vall d’Hebron Institute of Oncology, Barcelona, and colleagues, showed that the HER2-targeting antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) demonstrated durable responses, as well as improved median progression-free survival and overall survival in patients with breast cancer. Their updated survival results, presented during the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract 279P), demonstrated a significant benefit in prolonged estimated median overall survival, “high landmark survival,” and consistent safety data.
“These updated results continue to demonstrate the survival benefit of T-DXd in heavily previously treated patients with HER2-positive metastatic breast cancer,” the study authors concluded. “The efficacy and safety of T-DXd are currently undergoing further investigation in randomized controlled clinical trials.”
A total of 253 patients with HER2-positive breast cancer who experienced disease progression on the HER2-targeting antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) were enrolled in this study. Of the total, 184 participants received T-DXd at a dose of 5.4 mg/kg.
Patient age ranged from 20.2 to 83.1 years, and the number of prior therapy lines ranged from 0 to 16. At the most recent data cutoff, the median duration of overall survival follow-up was 29.2 months, and the updated median overall survival was 28.4 months; there were 91 overall survival events. The estimated overall survival rate at 18 months was 75%, and the estimate at 24 months was 58%.
Disclosure: For full disclosures of the study authors, visit oncologypro.esmo.org.
